AU2001286852A1 - Quinoline antibacterial compounds and methods of use thereof - Google Patents
Quinoline antibacterial compounds and methods of use thereofInfo
- Publication number
- AU2001286852A1 AU2001286852A1 AU2001286852A AU8685201A AU2001286852A1 AU 2001286852 A1 AU2001286852 A1 AU 2001286852A1 AU 2001286852 A AU2001286852 A AU 2001286852A AU 8685201 A AU8685201 A AU 8685201A AU 2001286852 A1 AU2001286852 A1 AU 2001286852A1
- Authority
- AU
- Australia
- Prior art keywords
- methods
- antibacterial compounds
- quinoline antibacterial
- quinoline
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 2
- 230000000844 anti-bacterial effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
- C07D215/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3 with oxygen atoms in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/60—Quinoline or hydrogenated quinoline ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22884400P | 2000-08-29 | 2000-08-29 | |
| US60228844 | 2000-08-29 | ||
| PCT/US2001/026810 WO2002018345A1 (fr) | 2000-08-29 | 2001-08-28 | Composes de quinoline antibacteriens et procedes d'utilisation de ceux-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2001286852A1 true AU2001286852A1 (en) | 2002-03-13 |
Family
ID=22858771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001286852A Abandoned AU2001286852A1 (en) | 2000-08-29 | 2001-08-28 | Quinoline antibacterial compounds and methods of use thereof |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1313708A1 (fr) |
| AU (1) | AU2001286852A1 (fr) |
| WO (1) | WO2002018345A1 (fr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2605481A1 (fr) * | 2005-04-21 | 2007-02-15 | Targanta Therapeutics Inc. | Fluoroquinolones phosphonees, leurs analogues antibacteriens, et methodes permettant de prevenir et de traiter des infections osseuses et articulaires |
| DK1901749T3 (en) * | 2005-05-18 | 2016-10-24 | Raptor Pharmaceuticals Inc | Aerosolized fluoroquinolones AND USES THEREOF |
| AU2013203605B2 (en) * | 2005-05-18 | 2016-09-29 | Horizon Therapeutics U.S. Holding Llc | Aerosolized fluoroquinolones and uses thereof |
| US8524735B2 (en) * | 2005-05-18 | 2013-09-03 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| US7838532B2 (en) | 2005-05-18 | 2010-11-23 | Mpex Pharmaceuticals, Inc. | Aerosolized fluoroquinolones and uses thereof |
| CA2739893C (fr) | 2008-10-07 | 2016-10-04 | Mpex Pharmaceuticals, Inc. | Inhalation de levofloxacine pour reduire une inflammation des poumons |
| US8815838B2 (en) | 2008-10-07 | 2014-08-26 | David C. Griffith | Aerosol fluoroquinolone formulations for improved pharmacokinetics |
| EP3569235A1 (fr) | 2009-09-04 | 2019-11-20 | Horizon Orphan LLC | Utilisation de lévofloxacine en aérosol pour traiter la fibrose kystique |
| CN114113353B (zh) * | 2020-08-31 | 2023-05-02 | 重庆华邦胜凯制药有限公司 | 分离检测加替羧酸乙酯和/或相关杂质的方法 |
| CN114113355B (zh) * | 2020-08-31 | 2023-05-30 | 重庆华邦胜凯制药有限公司 | Hplc法分离检测加替羧酸乙酯和/或相关杂质的方法 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3577089D1 (de) * | 1984-01-26 | 1990-05-17 | Abbott Lab | Antibakterielle chinolinderivate. |
| JPS60228479A (ja) * | 1984-04-26 | 1985-11-13 | Toyama Chem Co Ltd | 1,4−ジヒドロ−4−オキソナフチリジン誘導体およびその塩 |
| EP0181521A1 (fr) * | 1984-10-19 | 1986-05-21 | Otsuka Pharmaceutical Co., Ltd. | Composés d'acide 1-phényl substitué-4-oxo-3-quinoléine carboxylique |
| JPS61100568A (ja) * | 1984-10-19 | 1986-05-19 | Otsuka Pharmaceut Co Ltd | ベンゾヘテロ環化合物 |
| GB8429142D0 (en) * | 1984-11-19 | 1984-12-27 | Fujisawa Pharmaceutical Co | Quinolone compounds |
| EP0447484A1 (fr) * | 1988-12-06 | 1991-09-25 | The Upjohn Company | Composes de quinolone antibacteriens |
| AR030537A1 (es) * | 1999-11-05 | 2003-08-27 | Abbott Lab | Acidos quinolincarboxilicos y naftiridincarboxilico antibacterianos |
-
2001
- 2001-08-28 EP EP01966327A patent/EP1313708A1/fr not_active Withdrawn
- 2001-08-28 AU AU2001286852A patent/AU2001286852A1/en not_active Abandoned
- 2001-08-28 WO PCT/US2001/026810 patent/WO2002018345A1/fr not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| WO2002018345A1 (fr) | 2002-03-07 |
| EP1313708A1 (fr) | 2003-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU4520801A (en) | Novel substituted phenanthridinones and methods of use thereof | |
| AU2609901A (en) | Antimicrobial compositions and methods of use | |
| AU2002330943A1 (en) | Immunomodulatory compounds and methods of use thereof | |
| AU2001241474A1 (en) | Biosensor compositions and methods of use | |
| AUPR001000A0 (en) | Novel chemical compounds and their use | |
| AU2002225954A1 (en) | Dipeptidylpeptidases and methods of use | |
| AU2002314466A1 (en) | Withasol and methods of use | |
| AU2001280599A1 (en) | Compounds and methods | |
| AU2001253418A1 (en) | Compounds and methods | |
| AU2002224808A1 (en) | Use of thienopyrimidines | |
| AU2002213346A1 (en) | Osteopontin-coated surfaces and methods of use | |
| AU2001288972A1 (en) | Antipsychotic sulfonamide-heterocycles, and methods of use thereof | |
| AU2001243394A1 (en) | Compounds and methods | |
| AU2001286852A1 (en) | Quinoline antibacterial compounds and methods of use thereof | |
| AU2001273052A1 (en) | Antifungal compounds and methods of use | |
| AU2002219900A1 (en) | Minimal identification of features | |
| AU2001257163A1 (en) | Glycopeptide antibacterial compounds and methods of using same | |
| AUPQ872300A0 (en) | Compounds and methods | |
| AU2002214189A1 (en) | Methods of identifying inhibitory compounds and uses thereof | |
| AU2002363938A1 (en) | Methods and use of motoneuronotropic factors | |
| AU2001278951A1 (en) | Compounds and methods | |
| AU2001245414A1 (en) | Treatment of allergies | |
| AU2001274022A1 (en) | Use of substituted 1-amino-5-phenylpentane-3-ol and/or 1-amino-6-phenylhexane-3-ol compounds as medicaments | |
| AU4432001A (en) | Trityl-type compounds and their use | |
| AU2001261496A1 (en) | Luxo-sigma54 interactions and methods of use |